Dr. Jonathan Kil, CEO and CMO of Sound Pharmaceuticals, discusses recent advancements in hearing loss treatment. He highlights the company's journey over the past two decades, focusing on the development of SPI-1005, an investigational drug for sensorineural hearing loss and tinnitus. Currently in clinical trials, SPI-1005 has shown safety and efficacy in treating conditions like noise-induced hearing loss, Meniere's disease, and antibiotic-induced ototoxicity. Dr. Kil explains the science behind these therapies and their potential impact, offering insights into the future of pharmaceutical treatments for hearing loss.

#hearingloss #drugdevelopment #tinnitus

свернуть